Literature DB >> 2861077

Somatostatin-14 and somatostatin-28 pretreatment down-regulate somatostatin-14 receptors and have biphasic effects on forskolin-stimulated cyclic adenosine, 3',5'-monophosphate synthesis and adrenocorticotropin secretion in mouse anterior pituitary tumor cells.

S Heisler, C B Srikant.   

Abstract

Activation of somatostatin-14 (S-14) receptors on mouse AtT-20 pituitary tumor cells by S-14 or somatostatin-28 (S-28) inhibits forskolin-stimulated cAMP synthesis and ACTH secretion. In this study, the effects of prolonged exposure of cells to S-14 or S-28 was found to reduce, in a time- and concentration-dependent fashion, the density of S-14 receptors without affecting the affinity of these sites for [125I]Tyr11-S-14. This response was rapidly reversible after removal of peptide from incubation media. Additionally, S-14 and S-28 pretreatment also resulted in a time-dependent sensitizing effect on forskolin-stimulated cAMP formation and ACTH secretion which preceded S-14 receptor down-regulation. Enhancement of the forskolin response was concentration dependent, with maximal effects observed at 10(-8) M with either peptide. Higher pretreatment concentrations of S-14 resulted in an abolition of the enhanced biological response to forskolin; pretreatment with S-28 (10(-6) M) depressed forskolin- and (-)isoproterenol-induced cAMP formation below levels observed in nonpretreated cells. The enhancing effect of S-14 and S-28 required new protein synthesis, since it was partially blocked by cycloheximide; the depressor effect was independent of new protein synthesis. Both the enhanced and depressed forskolin responses after peptide pretreatment were reversible after withdrawal of S-14 or S-28; normalization of the forskolin response (cAMP formation and ACTH secretion) followed the return to control levels of S-14 receptor density. Pretreatment of cells with 10(-8) M or 10(-6) M S-28 increased and decreased, respectively, the ACTH secretory response to agonists which act in the absence of prior cAMP synthesis such as 8-bromo-cAMP, A-23187, and phorbol ester. The data suggest that S-14 receptor down-regulation is not causally associated with the sensitizing effects of S-14 and S-28 on adenylate cyclase and that the S-14 receptor may be also coupled to other effector systems which are involved in regulating the secretory function of AtT-20 cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861077     DOI: 10.1210/endo-117-1-217

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

1.  Tissue-specific distribution of cross-linked somatostatin receptor proteins in the rat.

Authors:  C B Srikant; K K Murthy; Y C Patel
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

Review 2.  Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

Authors:  Bassam Abu-Wasel; Caolan Walsh; Valerie Keough; Michele Molinari
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

3.  Resistance to a long-acting somatostatin analog (SMS 201-995) reversed by surgery in acromegaly.

Authors:  R Attanasio; P G Chiodini; A Liuzzi; P Orlandi; C De Palo; D Dallabonzana; A Lodrini; R Cozzi
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

4.  Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes.

Authors:  Neil Rajoriya; Dhiraj Tripathi; Joanna A Leithead; Bridget K Gunson; Sophie Lord; James W Ferguson; Gideon M Hirschfield
Journal:  World J Gastroenterol       Date:  2016-12-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.